
XYL · Industrials
Most investors see a premium industrial riding secular water tailwinds; the sharper frame is that Xylem is mid-transformation from capital equipment vendor to infrastructure data platform — and the stock is priced as though that transformation is already complete, while ROIC tells you it demonstrably isn't.
$125.21
$95.00
The AMI switching cost story is real — once a utility standardizes its metering network and staff on your head-end software, replacement is a decade-long civil engineering project, not a vendor swap — but ROIC languishing near the cost of capital reveals that the capital base has been roughly value-neutral, and the platform thesis needs to prove itself in the returns, not just the narrative.
Cash from operations beats reported earnings every year without exception — the hallmark of conservative accounting and genuine earnings quality — and net debt near zero with a strengthening cash position means this business can self-fund through a downturn without reaching for the dilution lever.
The organic growth guide for 2026 is honest but uninspiring, and the double 80/20 headwind combined with China orders collapsing creates a messy near-term picture; the MCS software platform and data center water intensity are genuine multi-year growth engines, but they remain more promise than demonstrated earnings power in the reported numbers.
The market has already awarded a full premium for secular water tailwinds and platform potential that haven't yet shown up in ROIC above the cost of capital — the base-case DCF points meaningfully lower, and with FCF yield barely above two and a half percent, there is almost no margin of safety against execution disappointment.
The China orders collapse is concrete and immediate, not hypothetical; Evoqua goodwill still suppresses ROIC and the integration clock is ticking; and the Infrastructure Act spending wave that inflated the order book will eventually crest, exposing a more rate-sensitive, cyclical demand picture than today's premium multiple implies.
Xylem's business quality is genuinely above average — AMI switching costs are real and compound with every new deployment, cash conversion is clean, and Evoqua added a services layer that nudges the revenue mix toward recurring. The problem is the price. At current multiples you are paying for a business where ROIC has expanded well above the cost of capital, software margins are visibly lifting the blended picture, and organic growth is accelerating — none of which has yet arrived simultaneously. The base-case DCF isn't being conservative; it's pointing lower with conviction. The strategic direction is correct. Every AMI network deployed deepens the switching cost moat. Data centers' water intensity is a real and structurally underappreciated demand driver that most industrial analysts haven't yet built into their models. The 80/20 portfolio rationalization is painful in 2026 but is exactly the kind of deliberate capital discipline that improves long-run returns. If MCS software and services reaches critical mass and ROIC begins a durable inflection above the cost of capital, this business re-rates on quality grounds — not just on growth optics. The single biggest concrete risk is ROIC staying pinned near the cost of capital for another cycle. The Evoqua acquisition loaded the balance sheet with goodwill and intangibles, and every dollar deployed at returns equal to WACC is economically neutral at best — quietly expensive at worst. If AMI project deferrals become cancellations, if China's order collapse spreads, or if integration synergies slip their schedule, the compounding math baked into the current valuation simply breaks down. A business priced for platform-level economics without yet earning platform-level returns has a long way to fall if patience runs out.